EA202090604A1 - Хроманмонобактамовые соединения для лечения бактериальных инфекций - Google Patents

Хроманмонобактамовые соединения для лечения бактериальных инфекций

Info

Publication number
EA202090604A1
EA202090604A1 EA202090604A EA202090604A EA202090604A1 EA 202090604 A1 EA202090604 A1 EA 202090604A1 EA 202090604 A EA202090604 A EA 202090604A EA 202090604 A EA202090604 A EA 202090604A EA 202090604 A1 EA202090604 A1 EA 202090604A1
Authority
EA
Eurasian Patent Office
Prior art keywords
present
compounds
pharmaceutically acceptable
chromanmonobactam
treatment
Prior art date
Application number
EA202090604A
Other languages
English (en)
Russian (ru)
Inventor
Тесфайе Бифту
Сяньхай Хуан
Вэйго ЛЮ
Вэйдун Пань
Минь Парк
Александер Пастернак
Ваньин Сунь
Хайфэн Тан
И Цзан
Original Assignee
Мерк Шарп энд Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп энд Доум Корп. filed Critical Мерк Шарп энд Доум Корп.
Publication of EA202090604A1 publication Critical patent/EA202090604A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA202090604A 2017-10-02 2018-09-27 Хроманмонобактамовые соединения для лечения бактериальных инфекций EA202090604A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762566779P 2017-10-02 2017-10-02
PCT/US2018/053039 WO2019070492A1 (en) 2017-10-02 2018-09-27 CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
EA202090604A1 true EA202090604A1 (ru) 2020-10-15

Family

ID=65994576

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090604A EA202090604A1 (ru) 2017-10-02 2018-09-27 Хроманмонобактамовые соединения для лечения бактериальных инфекций

Country Status (26)

Country Link
US (1) US11433055B2 (enExample)
EP (1) EP3691639B1 (enExample)
JP (1) JP7252948B2 (enExample)
KR (1) KR102425959B1 (enExample)
CN (2) CN111201021B (enExample)
AU (1) AU2018345523B2 (enExample)
CA (1) CA3076022C (enExample)
CL (1) CL2020000860A1 (enExample)
CO (1) CO2020004087A2 (enExample)
CR (1) CR20200148A (enExample)
DO (1) DOP2020000058A (enExample)
EA (1) EA202090604A1 (enExample)
ES (1) ES2968467T3 (enExample)
GE (1) GEP20227406B (enExample)
IL (1) IL273306B (enExample)
JO (1) JOP20200130A1 (enExample)
MA (1) MA50629A (enExample)
MX (1) MX2020003581A (enExample)
NI (1) NI202000023A (enExample)
PE (1) PE20201256A1 (enExample)
PH (1) PH12020550107A1 (enExample)
SA (1) SA520411571B1 (enExample)
SG (1) SG11202002575UA (enExample)
UA (1) UA126000C2 (enExample)
WO (1) WO2019070492A1 (enExample)
ZA (1) ZA202001721B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110156697B (zh) * 2019-05-30 2022-05-06 常州沃腾化工科技有限公司 一种1,2-二甲基-1,4,5,6-四氢嘧啶的合成方法
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
SI4175719T1 (sl) 2020-07-02 2025-07-31 Incyte Corporation Triciklične sečninske spojine kot zaviralci jak2 v617f
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US20240051931A1 (en) * 2020-12-03 2024-02-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Hdac inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
AU2021473165B2 (en) * 2021-11-09 2025-05-22 Guangzhou HC New Drug Research Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING β-LACTAM COMPOUND AND USE THEREOF
US11932637B2 (en) * 2021-11-18 2024-03-19 Merck Sharp & Dohme Llc Chromane amidine monobactam compounds for the treatment of bacterial infections
JP7671398B2 (ja) * 2021-11-18 2025-05-01 メルク・シャープ・アンド・ドーム・エルエルシー クロマンアミジンモノバクタム抗生物質
US12084430B2 (en) 2022-03-17 2024-09-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
EP4558137A2 (en) * 2022-07-18 2025-05-28 Merck Sharp & Dohme LLC Chromane amidine monobactam compounds for the treatment of bacterial infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684722A (en) 1986-01-06 1987-08-04 E. R. Squibb & Sons, Inc. Monosulfactams
US5250691A (en) * 1991-09-09 1993-10-05 E. R. Squibb & Sons, Inc. Heteroaryl derivatives of monocyclic beta-lactam antibiotics
CA2783572C (en) 2005-12-07 2016-08-09 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
EP1938822A1 (en) * 2006-12-21 2008-07-02 Novartis AG Combination therapy for the treatment of airways disease
EA031698B1 (ru) 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Человеческие анти-тау антитела
CA2815821C (en) 2010-11-29 2015-07-07 Pfizer Inc. Monobactams useful for treating bacterial infections
UY34585A (es) 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
MY172458A (en) 2012-05-31 2019-11-26 Teijin Pharma Ltd Therapeutic agent or prophylactic agent for dementia
US20140275007A1 (en) 2013-03-14 2014-09-18 Rempex Pharmaceuticals, Inc. Oxamazin antibiotics
US20160326157A1 (en) 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
PT3122745T (pt) 2014-03-24 2019-04-30 Novartis Ag Compostos orgânicos de monobactama para o tratamento de infeções bacterianas
TW202136296A (zh) 2014-06-27 2021-10-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
SG10201803472QA (en) 2014-10-31 2018-06-28 Abbvie Sarl Substituted chromanes and method of use
FR3031423B1 (fr) * 2015-01-06 2018-11-30 Centre National De La Recherche Scientifique Procede et dispositif de conversion de courant et vehicule comportant un tel dispositif
AU2016371600B2 (en) 2015-12-15 2021-02-18 Merck Sharp & Dohme Llc Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
JP7034929B2 (ja) * 2016-03-07 2022-03-14 メルク・シャープ・アンド・ドーム・コーポレーション 二環式アリールモノバクタム化合物及び細菌感染症を治療するためにそれらを使用する方法

Also Published As

Publication number Publication date
CO2020004087A2 (es) 2020-04-24
KR102425959B1 (ko) 2022-07-27
NZ762899A (en) 2024-07-26
AU2018345523B2 (en) 2021-10-21
KR20200058520A (ko) 2020-05-27
MA50629A (fr) 2021-03-31
JP2020536082A (ja) 2020-12-10
EP3691639B1 (en) 2023-11-15
IL273306B (en) 2022-04-01
IL273306A (en) 2020-04-30
EP3691639A1 (en) 2020-08-12
CL2020000860A1 (es) 2020-08-14
SG11202002575UA (en) 2020-04-29
JP7252948B2 (ja) 2023-04-05
US20200297702A1 (en) 2020-09-24
US11433055B2 (en) 2022-09-06
CA3076022A1 (en) 2019-04-11
BR112020006381A2 (pt) 2020-09-24
DOP2020000058A (es) 2020-09-15
GEP20227406B (en) 2022-08-25
CN111201021B (zh) 2024-08-23
ZA202001721B (en) 2023-02-22
EP3691639A4 (en) 2021-03-31
BR112020006381A8 (pt) 2023-04-11
CR20200148A (es) 2020-05-22
PE20201256A1 (es) 2020-11-16
PH12020550107A1 (en) 2020-12-07
MX2020003581A (es) 2020-07-22
UA126000C2 (uk) 2022-07-27
AU2018345523A1 (en) 2020-03-26
NI202000023A (es) 2020-09-24
ES2968467T3 (es) 2024-05-09
CN118496221A (zh) 2024-08-16
JOP20200130A1 (ar) 2020-05-28
CA3076022C (en) 2023-01-17
CN111201021A (zh) 2020-05-26
WO2019070492A1 (en) 2019-04-11
SA520411571B1 (ar) 2024-08-27

Similar Documents

Publication Publication Date Title
EA202090604A1 (ru) Хроманмонобактамовые соединения для лечения бактериальных инфекций
MX385731B (es) Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas.
MX2018010878A (es) Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
EA201890150A1 (ru) 3-тетразолил-бензол-1,2-дисульфонамидные производные в качестве ингибиторов металло-бета-лактамазы
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
MX2015012472A (es) Derivados de manosa para el tratamiento de infecciones bacterianas.
MX391911B (es) Compuesto antimicrobiano ((2r,3s,5r)-5-(4-amino-2-oxopirimidin-1(2h)- il)-3-((butoxióxidofosfor-il)oxi) tetrahidrofuran-2-il)metil butil fosfato, y el uso del mismo en infecciones.
EA202091118A1 (ru) Антибактериальные соединения
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
NZ758839A (en) Glycopeptide derivative compounds and uses thereof
EP2590978A4 (en) CARBAPENEM ANTIBACTERIAL AGENTS WITH NEGATIVE ANTI-GRAM ACTIVITY
EA201992370A1 (ru) Соединения и способы для лечения бактериальных инфекций
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
MX2017012539A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
EA202193211A1 (ru) Лечение синуклеопатий
MX2021003485A (es) Derivados de indano para uso en el tratamiento de infeccion bacteriana.
GEAP202416514A (en) Chromane amidine monobactam antibiotics
EA201491971A1 (ru) Антибактериальные хинолиновые производные
PH12020551620A1 (en) Compositions for preventing or treating dry eye
EA202190585A1 (ru) Производные индана для применения при лечении бактериальной инфекции
EA202090357A1 (ru) Химические соединения
EA202190617A2 (ru) Соединения-ингибиторы бета-лактамаз
TH1701007800A (th) ตัวยับยั้งเมทัลโล-บีตา-แลคทาเมส